CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo trial for prostate cancer halted early
Disease control TerminatedThis study tested a combination of two drugs—tivozanib and enzalutamide—in men with advanced prostate cancer that had stopped responding to standard hormone therapy. Enzalutamide blocks male hormones that fuel cancer growth, while tivozanib cuts off the tumor's blood supply. The …
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Promising prostate cancer combo trial stalls after just 7 patients
Disease control TerminatedThis phase II trial tested two drugs—denosumab and enzalutamide—together in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The goal was to see if the combination could slow cancer growth better than enzalutamide alone. Ho…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Cancer Trials Ireland • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Promising prostate cancer combo trial halted before results
Disease control TerminatedThis phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental cancer drug KZR-261 tested in early trial
Disease control TerminatedThis early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Kezar Life Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Promising cancer combo trial halted early
Disease control TerminatedThis study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Blood marker may predict prostate cancer drug response
Knowledge-focused TerminatedThis study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Kristoffer Rohrberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC